Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000551348 | SCV000628677 | uncertain significance | Neurofibromatosis, type 1 | 2017-04-27 | criteria provided, single submitter | clinical testing | In summary, this variant is a novel missense change with uncertain impact on protein function. It has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). This variant is not present in population databases (ExAC no frequency) and has not been reported in the literature in individuals with an NF1-related disease. This sequence change replaces glutamic acid with aspartic acid at codon 1908 of the NF1 protein (p.Glu1908Asp). The glutamic acid residue is moderately conserved and there is a small physicochemical difference between glutamic acid and aspartic acid. |
Ce |
RCV001726214 | SCV001961675 | uncertain significance | not provided | 2021-09-01 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001726214 | SCV002013069 | uncertain significance | not provided | 2019-11-26 | criteria provided, single submitter | clinical testing | Not observed in large population cohorts (Lek 2016); In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; Has not been previously published as pathogenic or benign to our knowledge |
Genome- |
RCV000551348 | SCV002560911 | uncertain significance | Neurofibromatosis, type 1 | 2022-03-15 | criteria provided, single submitter | clinical testing | |
MGZ Medical Genetics Center | RCV000551348 | SCV002579494 | likely pathogenic | Neurofibromatosis, type 1 | 2022-02-25 | criteria provided, single submitter | clinical testing |